Oncologist Radiotherapist INT
According to recent literature data, 50% of patients diagnosed with cancer undergo radiotherapy treatment; 95% of these develop skin reactions characterized mainly by swelling, redness, pigmentation, fibrosis, ulceration, pain, burning and itching.
The occurrence of the skin lesions is related with the onset of a series of complications, including a delay in the ongoing treatment, the worsening of painful forms, a negative psychological impact on the patients and a general deterioration of its quality of life.
The importance of preventing or slowing down the onset and the intensity of injuries is fundamental both to counteract the side effects of the acute phase, and to reduce the risk of the occurrence of chronic injuries which are currently irreversible.
For this reason, before undergoing the actual radiotherapy treatment, the patients undergo what is called “centering” process.
This is a very important phase of the therapy because it allows, through a Computed Tomography – CT scan, to precisely locate the position of the tumor and therefore to direct the beam of rays with extreme precision on the area where the mass of diseased cells is founded. The availability of sophisticated equipment in some hospitals, allows to perform radiotherapy treatment under the guidance of images and with a modulation of the beam of rays, based on the volume of the tumor, thus conveying more radiation on the tumor mass and shielding the healthy tissues.
Depending on the characteristics of the tumor, the radiotherapist oncologist will prescribe a different intensity of the radiation dose, expressed in the unit of measurement called gray – Gy.
It is the amount of dose administered that determines the side effects, their intensity and the time of onset, especially for what concerns skin lesions.
Oncologist Radiotherapist INT
A solution that, in addition to what is already listed for the preventive stage, has:
Jalosome® Soothing gel is a gel formulation created from the specific need to treat dermatitis induced by radiotherapy, in its various stages of skin irritation.
Welcare’s laboratory research has developed a product formulation that meets the needs of the cancer patient who undergo radiotherapy treatment.
Jalosome® Soothing gel contains 7 active ingredients, all with an active function within the product. It can be used in the preventive phase, to stimulate skin cell reproduction, so as to promptly respond to the skin damage induced by the radiotherapy treatment, reducing its effects, delaying its onset and its intensity.
Its effectiveness is also proven in already evident lesions, even of a high degree.
Jalosome® Soothing gel comes in a pack containing 4 vials of 10ml, for a total of 40ml of product. The division into 4 different airless bottles aims to reduce as much as possible the contact between the product and the external environment and the user’s hands, so as to minimize the risk of contamination.
The quantity needed to treat the body area that will be or is undergoing radiotherapy is calculated considering that each delivery, corresponding to 0.2 grams of gel, is sufficient for 16 cm2 of skin.
Nourishing, moisturizing and keeping the skin elastic is extremely important to avoid disorders resulting from excessive dryness, such as, for example, redness, irritation, flaking.
For this reason, Welcare has chosen to combine Jalosome® Soothing gel with a new formulation, Jalosome® Hydrating cream, with the aim of providing a solution that helps to maintain the skin integrity.
Jalosome® Hydrating comes in a package containing 1 bottle of 100 ml, with an airless dispensing system